EZ Traders Forum

[ToshacH]

Buying NGNM .10 today

NOGN - NeoGenomics, Inc.
Website: http://www.neogenomics.org
http://www.investorshub.com/boards/board.asp?board_id=1333


NeoGenomics, Inc. Announces the Appointment of Thomas H. White as CEO

2004-01-22 12:00 ET - News Release

Also News Release (U-NGNM.OB)


FORT MYERS, Fla., Jan. 22 /PRNewswire-FirstCall/ -- NeoGenomics, Inc. (BULLETIN BOARD: NGNM) announced today that Thomas H. White has joined the Company as its Chief Executive Officer.

Mr. White has considerable experience in leading and managing healthcare companies. Most recently, Mr. White was President and Chief Executive Officer of SmartPill Corporation, a biotech company headquarted in Buffalo, NY. SmartPill merged with APPRO Healthcare, Inc. to form SmartPill Diagnostics, Inc. Mr. White remained as Chief Operating Officer until joining NeoGenomics, Inc.

Prior to SmartPill, Mr. White was the President and Chief Executive Officer of ConPharma Home Healthcare, Inc. He lead the turnaround and growth of a 450-employee business, providing home infusion therapy, respiratory, medical equipment and nursing services through 35 locations in the U.S.

Mr. White also held senior management positions with Beverly Enterprises and the Upjohn Company. He has a BBA degree in Marketing and an MBA degree in Business Management and Finance from Western Michigan University.

As Chief Executive Officer for NeoGenomics, Mr. White will be responsible for all business operations, as well as the coordination of the Company's genomic research activities. Michael T. Dent, M.D. will continue as the Company's Chairman, President and Chief Medical Officer.

Dr. Dent, the Company's Chairman stated, "Mr. White brings a wealth of experience and strong business acumen to NeoGenomics. His leadership will contribute greatly towards the growing success of our clinical lab operations and the achievement of our research goals."

Mr. White had the following to say about his appointment, "I'm delighted to be joining NeoGenomics. It is a terrific company that is exceptionally well-poised for rapid growth over the next few years. My initial focus will be on expanding the Company's clinical laboratory operations with new products and increased geographic penetration. We also intend to begin expanding our research initiatives in the near future."

About NeoGenomics, Inc.

NeoGenomics, Inc. has established a state-of-the-art genetic/diagnostic or "Genostics" laboratory in Ft. Myers, FL. The Company's principle operations include providing cytogenetic and molecular biology diagnostic testing services to the oncology and perinatology sectors of the healthcare industry. The Company also conducts research activities for the early diagnosis of women's diseases, such as ovarian cancer, as well as diseases in prenates and infants. For additional information on NeoGenomics, please visit our web site at http://www.neogenomics.org/.

Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to establish its laboratory, develop useful applications from its planned research and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.

NeoGenomics, Inc.

CONTACT: Investors, Steven C. Jones of NeoGenomics, [phone], or
[e-mail]

Web site: http://www.neogenomics.org/